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Abstract
Background The UGT1A1*28 polymorphism, although
closely linked with CPT-11-related adverse effects, cannot
be used alone to guide individualized treatment decisions.
However, CPT-11 dosage can be adjusted according to
measured SN-38 pharmacokinetics. Our study is designed
to investigate whether there is a relationship between SN-
38 peak or valley concentrations and efficacy or adverse
effects of CPT-11-based chemotherapy. We retrospectively
studied 98 patients treated with advanced colorectal cancer
in various UGT1A1*28 genotype groups (mainly (TA)6/
(TA)6 and (TA)6/(TA)7 genotypes) treated with CPT-11 as
first-line chemotherapy in Shanghai.
Methods One hundred and sixty-four advanced colorectal
cancer patients were enrolled. To understand differences in
genotype expression, the frequency of UGT1A1*28 thy-
mine–adenine (TA) repeats in TATA box arrangement was
assessed by PCR with genomic DNA extracted from
peripheral blood. For ninety-eight cases with the (TA)6/
(TA)6 and (TA)6/(TA)7 genotypes treated with CPT-11 as
first-line chemotherapy, the plasma concentration of SN-38
was detected by HPLC 1.5 and 49 h after CPT-11 infusion.
X. Cai (&)  H. Ding  L. Wang
Department of Oncology, Shanghai First People’s Hospital,
Shanghai Jiaotong University, 100 Haining Road, Hongkou







Department of Oncology, Ruijin Hospital, Medical School,
Shanghai Jiaotong University, Shanghai 200025,
People’s Republic of China
e-mail: caowg52@hotmail.com
T. Liu
Department of Oncology, Zhongshan Hospital,
Fudan University, Shanghai 200032,
People’s Republic of China
e-mail: tsliuceu@gmail.com
X. Zhou
Department of Oncology, Huashan Hospital, Fudan University,
Shanghai 200040, People’s Republic of China
e-mail: xinli_zhou@yahoo.com
M. Wang
Department of Oncology, Changhai Hospital, Second Military
University, Shanghai 200433, People’s Republic of China
e-mail: wangmeib0211@hotmail.com
M. Zhong
Department of General Surgery, Renji Hospital, Medical School,




Department of General Surgery, Central Hospital in Jing’an
District, Shanghai 200040, People’s Republic of China
e-mail: zhaoziyimail@yahoo.com.cn
Q. Xu
Department of Oncology, Shanghai Tenth People’s Hospital,




J Cancer Res Clin Oncol (2013) 139:1579–1589
DOI 10.1007/s00432-013-1480-7
Efficacy and adverse effects were observed subsequently,
and the relationship between SN-38 plasma concentration
and efficacy or adverse effects within genotype groups, as
well as differences in efficacy and adverse effects between
(TA)6/(TA)6 and (TA)6/(TA)7 genotypes were analyzed
statistically.
Results One hundred and fourteen patients (69.51 %)
were identified with the (TA)6/(TA)6 genotype, forty-eight
patients (29.27 %) with the (TA)6/(TA)7 genotype, and two
patients (1.22 %) with the (TA)7/(TA)7 genotype. The
average peak and valley concentrations of SN-38 after
CPT-11 infusion and plasma bilirubin average levels
before and after CPT-11 treatment in the (TA)6/(TA)7
genotype group were all higher than those in (TA)6/(TA)6
group, and the difference was statistically significant
(p = 0.00). Stepwise regression analysis showed that SN-
38 peak and valley concentration was correlated with PFS
in the (TA)6/(TA)6 genotype. In the (TA)6/(TA)7 group,
SN-38 peak concentration was correlated with CPT-11
starting dose and OS, valley concentration correlated with
plasma bilirubin levels before CPT-11 treatment, delayed
diarrhea, and OS. For the (TA)6/(TA)6 genotype, mPFS of
the SN-38 peak concentration [43.2 ng/ml subgroup was
significantly longer than that of B43.2 ng/ml subgroup
(8.0 ± 0.35 vs. 6.5 ± 0.79 months, v2 = 17.18, p = 0.00)
with a relatively high incidence of Grade I/II myelosup-
pression; for the (TA)6/(TA)7 genotype, there was no sig-
nificant difference in mOS between the SN-38 valley
concentration [16.83 ng/ml and B16.83 subgroups
(17.3 ± 0.45 vs. 18.8 ± 0.50 months, v2 = 1.38,
p = 0.24), but the former had a higher incidence of Grade
III/IV mucositis and delayed diarrhea. For 2 (TA)7/(TA)7
cases, although 25 % dose reduction of CPT-11, which is
calculated according to body surface area, Grade IV bone
marrow suppression and Grade III delayed diarrhea still
occurred after CPT-11 treatment, though both adverse
effects resolved and did not recur again after a 50 % dose
reduction.
Conclusion The (TA)6/(TA)6 genotype and (TA)6/(TA)7
genotype accounted for the most, and (TA)7/(TA)7
genotype only account for a very small portion of
advanced colorectal cancer patients in Shanghai. For the
(TA)6/(TA)6 genotype, CPT-11 dosage can be increased
gradually to improve efficacy for patients with SN-38
peak concentration B43.2 ng/ml after CPT-11 infusion;
and for (TA)6/(TA)7 genotype patients, CPT-11 dosage
may be lowered appropriately to reduce serious adverse
effects such as bone marrow suppression and delayed
diarrhea without affecting the efficacy for those with SN-
38 valley concentration [16.83 ng/ml. For (TA)7/(TA)7
genotype patients, adverse effects should be closely
observed after treatment even if CPT-11 dosage has been
reduced.
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AUCSN-38 Area under the curve of SN-38
AUCSN-38G/AUCSN-38 The ratio of area under the curve
of SN-38G and SN-38
SAP Shrimp alkaline phosphatase
IS Internal standard
RECIST The response evaluation criteria
in solid tumors
CTCAE National Cancer Institute common




China has a high incidence of colorectal cancer due to a
variety of factors including lifestyle changes with 400,000
newly diagnosed cases each year. Colorectal cancer is the
second most common malignant tumor in Shanghai, with
incidence increasing by 3.67 times since the early 1970s.
Between 40 and 70 % patients will experience postoperative
recurrence and metastasis following radical surgery for
early-stage disease. CPT-11-based chemotherapy has been
supported by the research as a standard first-line treatment
for advanced colorectal cancer. However, Grade III/IV
bone marrow suppression or delayed diarrhea caused by
CPT-11 may occur in some patients during or after treatment,
which leads to treatment delays and affect patients’ quality of
life (Douillard et al. 2000; Innocenti et al. 2004). Many
studies have confirmed that UGT1A1 is the main metabolic
enzyme that inactivates SN-38, the active product of CPT-
11, into SN-38G. Ethnic differences exist in UGT1A1
enzyme activity and gene polymorphisms (Kaniwa et al.
2005), which are closely related to CPT-11 adverse effects
(Innocenti et al. 2004; Massacesi et al. 2006) but they are
uncertain with efficacy (Shulman et al. 2011; Liu et al. 2008).
In addition, studies have found that AUCSN-38 or
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AUCSN-38G/AUCSN-38 is associated with neutropenia after
CPT-11 treatment (Hirose et al. 2012; Canal et al. 1996),
which indicate that CPT-11 or SN-38 pharmacokinetics is as
important as UGT1A1 gene polymorphism analysis in pre-
dicting CPT-11-related adverse effects, even in dose indi-
vidualization sets. Presently, data are limited about the role
of UGT1A1*28 genotype and SN-38 pharmacokinetics in
predicting CPT-11 efficacy and adverse effects, so our study
reviewed the plasma SN-38 peak and valley concentration,
treatment efficacy, and adverse effects in 98 cases with
(TA)6/(TA)6 and (TA)6/(TA)7 genotypes who were treated
with CPT-11 as first-line chemotherapy, in order to deter-
mine whether there is a relationship between plasma SN-38
peak and valley concentration and efficacy or adverse effects
in patients with different genotypes, and provide theoretical
basis for CPT-11 treatment individualization based on




A total of 164 hospitalized patients with local advanced and
metastatic colorectal cancer were eligible for the study.
Disease was confirmed with pathological and imaging data
in Zhongshan Hospital, Huashan Hospital affiliated with
Fudan University, Ruijin hospital, Renji hospital affiliated
with Shanghai Jiaotong University Medical College,
Changhai hospital affiliated with the Second Military Uni-
versity, Shanghai No. 1 and No. 10 People’s Hospital, and
the Central Hospital of Jing’an District from April 2010 to
January 2012. Of the eligible patients, 117 were males and
47 were females, aged from 26 to 75 years with a median
age of 60 years, and included 100 cases of colon cancer and
64 cases of rectal cancer. Twenty cases had stage IIIb dis-
ease and 144 cases had stage IV disease according to the
AJCC Cancer Staging standard (6th edition). Inclusion
criteria were as follows: ECOG physical status scores from
0 to 2, with measurable disease not treated and life expec-
tancy of C3 months; of all the 164 cases, 98 cases were
assigned to receive a modified FOLFIRI chemotherapy
regimen for at least 4 cycles as first-line palliative chemo-
therapy after excluding chemotherapy contraindications
and obtaining informed consent. Plasma bilirubin and
transaminase level could not exceed 1.5 times and 5 times
the normal upper limit for patients with liver metastases.
Exclusion criteria such as pregnant or lactating women,
patients with complete or incomplete intestinal obstruction
or with a history of chronic enteritis or extensive bowel
resection, or with central nervous system metastases, having
been seriously allergic to drugs and its excipients used in the
treatment, evaluable lesions which had received radiother-
apy or other treatments, vital organ dysfunction, history of
other malignancies (cervical carcinoma in situ or skin basal
cell carcinoma excluded) and poor compliance.
About 2 ml of peripheral blood sample (anticoagulated
with EDTA) was obtained from each patient before che-
motherapy for UGT1A1*28 genotype analysis, and then
the patients received FOLFIRI chemotherapy 1.5-h infu-
sion of CPT-11 (180 mg/m2) and 2-h infusion of leuco-
vorin (400 mg/m2), followed by 5-fluorouracil bolus
(400 mg/m2) on day 1 and a 46-h continuous infusion
(2,400 mg/m2) for each cycle, repeated every 2 weeks.
About 2 ml of peripheral blood sample was taken 1.5 and
49 h after CPT-11 infusion for SN-38 plasma concentration
detection by HPLC (Hirose et al. 2012; Schoemaker et al.
2003), and CPT-11 dosage was lowered by 20–25 % in
case of Grade III adverse effects.
UGT1A1*28 genotype analysis
Genomic DNA was extracted with DNA extraction kit
(Qiagen Inc, Valencia, CA, USA) for PCR amplification.
Prime sequences were designed as follows: Upstream: 50-
TCCCTGCTACCTTTGTGGAC-30, downstream: 50-AG-
CAGGCCCAGGACAAGT-30. The PCR mix was (25 ll):
2 ll of 109 PCR buffer with 15 mM MgCl2, 2 ll of dNTP
(2.5 mM), 1 ll of Primers (10 lm), 1 ll of DNA templates,
0.2 ll of DNA Taq polymerase (5U/ll), and 18.8 ll of
ddH2O. Amplification procedure was as follows: a initial
denaturation step at 94 C for 5 min; followed by 40 cycles
of denaturation (94 C for 15 s), annealing (55 C for 25 s)
and extension (72 C for 50 s), and finally, extension at
72 C for 7 min. If the PCR product band is clear by elec-
trophoresis, take 5 ll of eligible specimen, mixed by adding
2 ll SAP, kept at 37 C for 60 min and 80 C for 15 min,
and then saved at 4 C. Took 3 ll positive PCR hydrolysates,
1 ll sequencing reagent (bigdye), and 2 ll sequencing pri-
mer for PCR amplification: initial denaturation at 96 C for
1 min, followed by 25 cycles of denaturation (96 C for
10 s), annealing (50 C for 5 s) and extension (60 C for
4 min), and then stored at 4 C. The sequencing product was
sequenced in DNA sequencing instrument (ABI-373, PE
corp., USA) after being purified. Sequencing results were
displayed and analyzed with GeneMapper software.
SN-38 plasma concentration detection
SN-38 and IS (acetone) were dissolved with dimethyl
sulfoxide into 1.0 mg/ml stock solution stored at -80 C.
SN-38 reference standard plasma was prepared at a con-
centration range of 2–500 ng/ml with blank plasma. We
then took 200 ll of the mentioned plasma, vortexed with
acetonitrile (100 ng/ml) for 1 min, and centrifuged at
J Cancer Res Clin Oncol (2013) 139:1579–1589 1581
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9,500 rpm for 10 min, and then tested after taking 200 ll
supernatant vortexed with 100 ll hydrochloric acid (1 mol/L)
for 30 s. The standard curve and linear regression were pre-
pared by taking the ratio of peak area of SN-38 and IS as the
vertical axis. Chromatographic condition: WatersNova-Pak
C18 Guard column (20 mm 9 3.9 mm, 5 lm of particle
diameter); mobile phase: disodium hydrogen phosphate
(0.05 mol/L, pH = 4.0, containing 0.05 mol/L 1-heptane-
sulfonic acid)-acetonitrile (75:25, v/v). Testing condition:
flow rate of 1 ml/min, column temperature at 25 C, excita-
tion wavelength at 370 nm, and emission wavelength at
470 nm. The retention time for SN-38 and IS was 15.4 and
17.8 min under the experimental condition.
Evaluation criteria and follow-up
The first efficacy follow-up was performed for all patients by
imaging scans after 3 cycles of chemotherapy, and partial
remission required reconfirmation at least 4 weeks after initial
assessment. Re-evaluation was to be done every 3 cycles until
disease progression and patients to be followed for overall
survival every 3 months. Patients could receive other che-
motherapy or best supportive care after disease progression,
but not include targeted therapy. The median follow-up was
16 month. Tumor efficacy was evaluated using RECIST, and
toxicity was graded according to CTCAE version 3.0.
Statistical analyses
Data were expressed as mean ± standard deviation. Prog-
nostic factors such as mPFS and mOS were calculated using
the Kaplan–Meier method, and survival differences were
analyzed by log rank test. A t test was used to compare the
difference between the groups and a chi-square test to
compare count data. Degree of adverse effects, plasma
concentration, and efficacy was accessed by variance anal-
ysis. All values were two-sided, and statistical significance
was accepted at the p \ 0.05 level. SPSS version 16.0 soft-
ware (SPSS Inc., USA) was used for all statistical analyses.
Results
UGT1A1 polymorphism for patients with advanced
colorectal cancer in Shanghai
One hundred and fourteen patients (69.51 %) were identi-
fied with the (TA)6/(TA)6 genotype, forty-eight patients
(29.27 %) with the (TA)6/(TA)7 genotype, and two patients
(1.22 %) with the (TA)7/(TA)7 genotype (for sequencing
results, see Fig. 1), and there were no statistical differences
in age, gender, ECOG performance score, primary tumor
site, TMN staging, and chemotherapy order between
Fig. 1 Sequencing results for (TA)6/(TA)6, (TA)6/(TA)7, and (TA)7/(TA)7 genotypes with GeneMapper software. a (TA)6/(TA)6 genotype,
b (TA)6/(TA)7 genotype, c: (TA)7/(TA)7 genotype
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(TA)6/(TA)6 and (TA)6/(TA)7 groups except for CPT-11
dosage reduction in the (TA)6/(TA)7 group (see Table 1).
SN-38 peak and valley concentration after CPT-11
infusion and plasma bilirubin level before and
after treatment for (TA)6/(TA)6 and (TA)6/(TA)7
groups treated with first-line chemotherapy
SN-38 average peak and valley concentration after CPT-11
infusion was 45.57 ± 19.38 and 8.67 ± 5.45 ng/ml,
respectively, for the (TA)6/(TA)6 genotype group, and
71.80 ± 9.15 and 15.39 ± 7.25 ng/ml for the (TA)6/(TA)7
genotype, and the difference was statistically significant
(t = 6.39, p = 0.00; t = 4.82, p = 0.00). Plasma bilirubin
levels were 9.42 ± 2.43 and 9.56 ± 2.26 lmol/L for (TA)6/
(TA)6 group, and 13.91 ± 3.90 and 14.44 ± 2.99 lmol/L
for (TA)6/(TA)7 group before and after treatment, respec-
tively, with significant difference between the groups
(t = 6.69, p = 0.00; t = 8.46, p = 0.0) but without signif-
icant difference before and after treatment within groups
(t = 0.35, p = 0.72; t = 0.53, p = 0.60), see Fig. 2.
Stepwise regression analysis between SN-38 peak
and valley concentration and efficacy, adverse effects
Taking SN-38 peak and valley concentration as dependent
variables, and adverse reactions, short-term effect, PFS,
and OS as independent variables, stepwise regression
analysis showed that, in the (TA)6/(TA)6 group, SN-38
peak and valley concentration was related to PFS, but in
the (TA)6/(TA)7 genotype, SN-38 peak concentration was
related to CPT-11 starting dose and OS, and the valley
concentration was related to plasma bilirubin levels
before CPT-11 treatment, delayed diarrhea incidence,
and OS (regression equation coefficients are shown in
Table 2).
Analysis of SN-38 peak, valley concentration
correlation with efficacy and adverse effects
of the subgroups in (TA)6/(TA)6 and (TA)6/(TA)7
genotypes
According to the corrected predictive values and standard
deviations of SN-38 peak and valley concentration
(45.49 ± 2.29 and 8.67 ± 0.74 ng/ml; 71.58 ± 2.07 and
15.25 ± 1.58 ng/ml), the (TA)6/(TA)6 genotype was divi-
ded into subgroups for the analysis by peak and valley
concentration [43.2 or B43.2 ng/ml and [9.41 or
B9.41 ng/ml, respectively. The (TA)6/(TA)7 genotype was
divided similarly with boundaries at[73.65 or B73.65 ng/ml
and [16.83 or B16.83 ng/ml, respectively. We found that
mPFS for the SN-38 peak concentration [43.2 ng/ml sub-
group was significantly higher than that for the B43.2 ng/ml
subgroup (8.0 ± 0.35 vs. 6.5 ± 0.79 months, v2 = 17.18,
p = 0.00) only with a relatively high incidence of Grade I/II
myelosuppression in the former, but there was no significant
difference in mPFS between the [9.41 and B9.41 ng/ml
subgroups (7.5 ± 0.25 vs. 7.0 ± 0.49 months, v2 = 0.75,
Table 1 Comparison of clinical
characteristics between (TA)6/
(TA)6 and (TA)6/(TA)7 groups
Clinical characteristics 6/6 genotype (n = 114) 6/7 genotype (n = 48) F P






Age (year) 57.54 ± 10.38 58.35 ± 10.06 0.21 0.65
Primary tumor site 0.66 0.50
Colon 66 34
Rectum 48 14
TMN staging 3.86 0.19
IIIb 12 8
IV 102 40
Chemotherapy order 0.42 0.58
First line 74 24
Second line 40 24
CPT-11 starting dosage (mg) 297.72 ± 35.30 299.17 ± 43.46 0.05 0.83
CPT-11 dosage reduction 23.67 0.00
Yes 8 17
No 106 31
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p = 0.39) for the (TA)6/(TA)6 genotype; no significant dif-
ference was found in mOS between SN-38 peak concentration
[73.65, B73.65 ng/ml subgroups and valley concentration
[16.83 ng/ml, B16.83 subgroups (18.6 ± 1.30 vs.
16.3 ± 0.51 months, v2 = 2.83, p = 0.09; 17.3 ± 0.45 vs.
18.8 ± 0.50 months, v2 = 1.38, p = 0.24), but the
[16.83 ng/ml subgroup had a higher incidence of Grade III/
IV mucositis and delayed diarrhea than B16.83 subgroup
(F = 5.58, p = 0.03; F = 19.60, p = 0.00, see Fig. 3;
Table 3) for the (TA)6/(TA)7 genotype.
Fig. 2 Comparison of SN-38 peak or valley concentrations after
CPT-11 infusion and plasma bilirubin levels before and after CPT-11
treatment between (TA)6/(TA)6 and (TA)6/(TA)7 genotypes. a SN-38
peak and valley concentrations were 45.57 ± 19.38 and
8.67 ± 5.45 ng/ml for (TA)6/(TA)6 genotype, and 71.80 ± 9.15 and
15.39 ± 7.25 ng/ml for (TA)6/(TA)7 genotype after CPT-11 infusion,
which were lower than the former with significant difference
(t = 6.39, p = 0.00; t = 4.82, p = 0.00). b Plasma bilirubin level
was 9.42 ± 2.43 and 9.56 ± 2.26 lmol/L for (TA)6/(TA)6 genotype,
and 13.91 ± 3.90 and 14.44 ± 2.99 lmol/L for (TA)6/(TA)7 geno-
type before and after treatment with significant difference between
genotypes (t = 6.69, p = 0.00; t = 8.46, p = 0.0) but without
significant difference before and after treatment within genotype
(t = 0.35, p = 0.72; t = 0.53, p = 0.60)
Table 2 Stepwise regression











Constant -9.53 7.47 -1.28 0.21
PFS 8.48 1.12 0.67 7.58 0.00
SN-38 valley concentration
Constant -3.28 2.42 -1.36 0.18
PFS 1.84 0.36 0.51 5.08 0.00
(TA)6/(TA)7 genotype
SN-38 peak concentration
Constant 17.78 9.70 1.83 0.08
CPT-11 starting dosage 0.08 0.03 0.45 2.86 0.01
OS 1.78 0.64 0.44 2.80 0.01
SN-38 valley concentration
Constant -5.93 6.21 -0.95 0.35
Delayed diarrhea 3.64 1.05 0.47 3.46 0.00
OS 1.56 0.43 0.49 3.60 0.00
Bilirubin level before treatment -0.70 0.25 -0.38 -2.82 0.01
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SN-38 peak, valley concentration, plasma bilirubin,
and adverse effects for (TA)7/(TA)7 genotype
SN-38 average peak and valley concentration after CPT-11
infusion were 113.4 and 33.18 ng/ml, and the average
plasma bilirubin levels before and after treatment were
20.9 and 24.1 lmol/L. Although 25 % dose reduction of
CPT-11, which is calculated according to the body surface
area, Grade IV bone marrow suppression and Grade III
delayed diarrhea still occurred after CPT-11 treatment in 2
(TA)7/(TA)7 cases, both adverse effects resolved and did
not recur after a 50 % dose reduction.
Discussion
Clinical administration dosage is generally calculated
according to the body surface area or weight presently
(Reilly and Workman 1993), which is the group average
dose, but in fact, only a part of drugs with low toxicity and
conventional administration, which doses calculated as
above, may get satisfactory effects. The plasma concen-
tration may be affected by drug absorption, distribution,
metabolism, and excretion, even small changes in plasma
concentration may cause efficacy differences and lead to
serious adverse effects. Anti-tumor therapy is entering the
Fig. 3 mPFS and mOS of the subgroups in (TA)6/(TA)6 and (TA)6/
(TA)7 genotypes A in (TA)6/(TA)6 genotype, mPFS of SN-38 peak
concentration [43.2, B43.2 ng/ml subgroup: 8.0 ± 0.35 versus
6.5 ± 0.79 months, v2 = 17.18, p = 0.00 (A1); mPFS of SN-38
trough concentration [9.41, B9.41 ng/ml subgroup in (TA)6/(TA)6
genotype: 7.5 ± 0.25 versus 7.0 ± 0.49 months, v2 = 0.75, p = 0.39
(A2)
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era of individualized treatment, through the use of bio-
logical markers, drug metabolism genes, or pharmacoki-
netics detection, etc. The purpose of individualized
treatment for advanced colorectal cancer is to improve
efficacy and/or to avoid and reduce the incidence of
adverse effects (Gamelin et al. 2008; Ychou et al. 2003;
Fety et al. 1998; Kleibl et al. 2009; Van Kuilenburg et al.
2002; Chang et al. 2009; Liu et al. 2011). CPT-11 is
metabolized to its active product SN-38 by hCES in vivo
and mainly inactivated to SN-38G by UGT1A1. It is gen-
erally believed that SN-38 determines activity and toxicity;
however, most studies have not found a correlation
between single-nucleotide polymorphisms and enzyme
activity in UGT1A1 (Wu et al. 2004; Charasson et al.
2004), However, the UGT1A1 gene polymorphism can
cause decline or absence of enzyme activity. A number of
studies have indicated that the UGT1A1*28 homozygous
genotype [(TA)7/(TA)7 genotype] may lead to weakening
of SN-38 glucuronidation, which is an important risk factor
for CPT-11-associated adverse effects such as delayed
diarrhea and myelosuppression (Marcuello et al. 2004; Iyer
et al. 2002; Paoluzzi et al. 2004). Our results showed that
(TA)6/(TA)6 and (TA)6/(TA)7 genotypes accounted for
69.51 and 29.27 % of patients, respectively, and the (TA)7/
(TA)7 genotype only for 1.22 % of the 164 enrolled
patients in Shanghai, and that genotype had no association
with age, gender, ECOG performance score, primary tumor
site, TMN staging, or chemotherapy background, which
was similar to other domestic studies (Yang et al. 2009;
Zhang et al. 2007), but the proportion was lower for (TA)6/
(TA)6 and (TA)6/(TA)7 genotypes than foreign studies
(Iyer et al. 2002; Coˆte´ et al. 2007; Toffoli et al. 2006;
Braun et al. 2008); it is also explained that CPT-11-related
adverse effects are lower in Chinese than in foreigners.
Although the UGT1A1*28 heterozygous genotype
[(TA)6/(TA)7 genotype] can lead to decrease in UGT1A1
activity, gene polymorphism analysis alone cannot be used
to direct individualized treatment of CPT-11 because
changes also occur in enzyme activity for this genotype
with individual difference. Pharmacokinetic studies have
shown that (TA)7/(TA)7 genotype has higher AUCSN-38
than (TA)6/(TA)6 and (TA)6/(TA)7 genotypes (Iyer et al.
2002), with CPT-11 reaching peak concentration 1.5 h
after infusion, terminal half-life of 10.8 h, and fall to valley
level of about 30 ng/ml 25.5 h roughly after infusion
(Sumiyoshi et al. 1995); in addition, 5-fluorouracil dose not
change CPT-11 metabolism in vivo in a certain range of
dosage (Ducreux et al. 1999; Saltz et al. 1996). These
results can help to give guidance on CPT-11 individualized
treatment by plasma concentration detection. Despite
(TA)6/(TA)6 and (TA)6/(TA)7 genotypes accounting for
most cases, there are no detailed reports before about the
differences in terms of efficacy and adverse effects after
first-line treatment with CPT-11. Our study found that the
average peak and valley concentrations of SN-38 in (TA)6/
(TA)6 genotype were higher than those in (TA)6/(TA)7
genotype after CPT-11 infusion; although average plasma
bilirubin was at normal levels in both genotypes, the levels
in (TA)6/(TA)7 genotype are also higher than that in (TA)6/
(TA)6 genotype before and after treatment with significant
difference, which was consistent with the findings of
Rouits et al. (2008). The cause for this phenomenon is that
bilirubin and SN-38 are both substrates of UGT1A1, and
abnormality in bilirubin glucuronidation leaves, bilirubin
level elevated when UGT1A1 activity decreases, while
CPT-11 metabolism may also be abnormal because of the
substrate competition, which leads to elevation of SN-38
concentration.
Stepwise regression analysis showed that SN-38 average
peak and valley concentration were associated with PFS in
the (TA)6/(TA)6 genotype; however, SN-38 peak concen-
tration was associated with CPT-11 starting dosage and
OS, and valley concentration was associated with plasma
bilirubin levels before CPT-11 treatment, delayed diarrhea,
and OS in (TA)6/(TA)7 genotype. So we divided the two
genotypes into four subgroups according to the upper and
lower limit of the corrected predictive values and standard
deviations for SN-38 average peak and valley concentra-
tions, in order to analyze the relationship between plasma
concentration and efficacy or adverse effects in the sub-
groups. The results showed that the mPFS of the SN-38
peak concentration[43.2 ng/ml subgroup was significantly
higher than that of B43.2 ng/ml subgroup with a relatively
high incidence of Grade I/II myelosuppression in the
(TA)6/(TA)6 genotype, while there was no significant dif-
ference in mOS between SN-38 valley concentration
[16.83 ng/ml and B16.83 subgroups, but the former had a
higher incidence of Grade III/IV mucositis and delayed
diarrhea in (TA)6/(TA)7 genotype. This suggested that
CPT-11 dosage can be gradually increased to improve
treatment efficacy in the SN-38 peak concentration
B43.2 ng/ml subgroup after CPT-11 infusion without
serious adverse effects for patients with the (TA)6/(TA)6
genotype (in our study, 55.41 %(41/74) of (TA)6/(TA)7
genotype with SN-38 peak concentration B43.2 ng/ml,
which means more than half of the patients require dose
adjustment), while CPT-11 dosage may be appropriately
lowered to reduce the incidence of serious adverse effects
without affecting the efficacy in the SN-38 valley con-
centration [16.83 ng/ml subgroup for the (TA)6/(TA)7
genotype. SN-38 peak and valley concentration and plasma
bilirubin level in the (TA)7/(TA)7 genotype were signifi-
cantly higher than that in the (TA)6/(TA)7 genotype, while
the incidence of serious adverse effects was consistent with
other studies (Marcuello et al. 2004; Iyer et al. 2002a, b;
Paoluzzi et al. 2004).
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Conclusions
In summary, our study suggests that the UGT1A1*28
(TA)6/(TA)6 and (TA)6/(TA)7 genotypes account for most
patients, while the homozygous mutant genotype only
accounts for a very small portion of patients with advanced
colorectal cancer in Shanghai. For the (TA)6/(TA)6 and
(TA)6/(TA)7 genotypes, UGT1A1*28 gene polymorphism
in combination with SN-38 pharmacokinetics analysis
provides a good theoretical basis for CPT-11 individual-
ized treatment; however, it should be verified by further
expanding sample sizes and repeated determination of SN-
38 plasma concentration after dosage adjustment, in order
to improve efficacy and meanwhile avoid or reduce serious
adverse effects. For the (TA)7/(TA)7 genotype, despite the
reduction in initial treatment dose, further adjustment of
CPT-11 dosage still should be done according to adverse
effects after treatment.
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